Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

What’s Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

By Vandana Singh
February 20, 1:30 PM
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

CMMB

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News

Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?

By Vandana Singh
February 20, 1:24 PM
FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma.

RAPT

Read More
3 minute read
  • Biotech
  • General
  • News

Scilex Holding Company Announces Publication In Anesthesiology Journal Of Results From An Investigator-Initiated Research Study Using ZTlido For The Treatment Of Chronic Neck Pain

By Benzinga Newsdesk
February 20, 10:16 AM
The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%.2 There are currently no approved medical treatments for neck pain in the U.S.The study was a

SCLX

Read More
1 minute read
  • Biotech
  • Events
  • General
  • News

Omeros Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use In Nine Patients With Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

By Benzinga Newsdesk
February 20, 10:15 AM
Omeros Corporation (NASDAQ:OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy

OMER

Read More
1 minute read
  • Biotech
  • General
  • News

RedHill’s Published Data Shows That Opaganib Protects Against Radiation-Induced Lung Inflammation And Fibrosis

By Benzinga Newsdesk
February 20, 10:07 AM
The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing

GILD

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • News

ARS Pharma Announces Topline Results From Repeat Dosing Study Of neffy Under Nasal Allergen Challenge Conditions, Readies Data For Response To FDA’s Complete Response Letter

By Benzinga Newsdesk
February 20, 10:03 AM
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection Company believes completion of

SPRY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation For AOC 1044 For Treatment Of Duchenne Muscular Dystrophy In People With Mutations Amenable To Exon 44 Skipping

By Benzinga Newsdesk
February 20, 10:01 AM
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food

RNA

Read More
3 minute read
  • Biotech
  • General
  • News

Teva Presents New Data Supporting Safety, Tolerability And Target Engagement Of Anti-TL1A Antibody At The 2024 ECCO Annual Meeting

By Benzinga Newsdesk
February 20, 9:55 AM
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-'574)1Anti-TL1A (TEV-'574) was shown to be safe and well-tolerated, with a low incidence of antidrug

SNY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Why AstraZeneca Stock Is Trading Higher Tuesday

By Vandana Singh
February 20, 9:54 AM
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy. AstraZeneca's datopotamab deruxtecan awaits FDA decision in Q4 2024 for nonsquamous NSCLC.

AZN

Read More
2 minute read
  • Biotech
  • General
  • News

Charles River Collaborates With Pluristyx, Expanding Its Portfolio Of Human Pluripotent Stem Cells

By Benzinga Newsdesk
February 20, 9:45 AM
The addition of ES cells and iPSCs will enhance Charles River's portfolio of powerful research tools supporting acceleration of therapeutic development.Charles River Laboratories International, Inc. (NYSE:CRL) today

CRL

Posts pagination

Previous 1 … 89 90 91 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service